Tumor-Treg-Targeting
Financiado
Training Network for the education of the next generation scientist in targeting...
Training Network for the education of the next generation scientist in targeting the supressive capacity of regulatory T cells specifically within tumours
Tumour immune-therapy has made dramatic improvements in recent years, saving the lives of cancer patients who just a
few years ago would have been considered untreatable. It thereby became apparent that one specific type of immune...
Tumour immune-therapy has made dramatic improvements in recent years, saving the lives of cancer patients who just a
few years ago would have been considered untreatable. It thereby became apparent that one specific type of immune cell,
so called regulatory T-cells, critically hampers the efficacy of tumour immune-therapy. Tumours, however, attract and exploit
the immune-regulatory function of Tregs to dampen local immune responses and to induce local tolerance.
In recent years, inhibitors that directly target immune-suppressive mechanisms of T cells have found clinical application with
great success. The clinical application of these so called check-point inhibitors, however, is accompanied by severe side
effects in treated patients. Thus improvement of the efficacy of current immune-therapeutic treatments is a major unmet
need. This proposal will employ the newest developments in antibody design to target the next generation of biologics right
towards tumour-residential Tregs or directly into the tumour micro-environment itself. In this way we will be able to
specifically shift the local immune suppressive environment within tumours, while leaving tissue homeostasis in noncancerous
tissues unaffected, and thus diminish treatment associated side-effects.
The here proposed project combines the expertise of fundamental immunologist, tumour immunologists and cell biologists
with that of a life-science biotechnology company and that of experts in clinical cancer research to address this aspect. This
group will lead a training network that aims at educating a new generation of researchers, who will be able to bridge the
innovation gap between, on the one hand, early discoveries in tumour-immunology as well as in antibody technology and, on
the other hand, the efficient translation and clinical validations of these findings in patients.
ver más
Duración del proyecto: 63 meses
Fecha Inicio: 2017-08-02
Fecha Fin: 2022-11-30
Fecha Fin: 2022-11-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2022-11-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
MSCA-ITN-2017:
Innovative Training Networks
Cerrada
hace 7 años
Presupuesto
El presupuesto total del proyecto asciende a
1M€
Líder del proyecto
UNIVERSIDAD DE NAVARRA
No se ha especificado una descripción o un objeto social para esta compañía.
Total investigadores
848
Total investigadores
848
N.D. |
Participante